The submissions are supported by data from a phase 3 study that evaluated mirabegron in 91 patients aged 3 to 17 years with NDO on clean intermittent catheterization.
The approval was based on data from the pivotal phase 3 EMPOWUR study.
In a study, approximately half of patients did not experience resolution of overactive bladder symptoms after anterior prolapse repair surgery.
The role of alpha adrenergic blockers in the treatment of urinary dysfunction and associated symptoms in women remains unclear.
In a study, only 39% of patients with overactive bladder continued BTX therapy for more than 5 years.
Adherence to diuretic therapy decreases as lower urinary tract symptoms increase in severity, according to a new study.
Physicians should carefully weigh the risks against the potential benefits before prescribing anticholinergics, according to investigators.
In a study, patients with chronic periodontitis and overactive bladder (OAB) had significantly fewer teeth (12.8 vs 21.5) compared with patients who did not have OAB.
At 52 weeks, 71.1% of patients treated with vibegron experienced at least a 50% decline in total incontinence episodes from baseline.
In a pilot study, the eCoin device yielded a dry rate of 30.33% at 36 weeks.